GC Green Cross announced on June 17 that it has signed a strategic partnership agreement with Abclone, a company specializing in anticancer therapeutics, to jointly research and develop next-generation in vivo CAR-T therapies.


Jaeuk Jung, Head of R&D at GC Green Cross (left), and Jongseo Lee, CEO of Abclon, are taking a commemorative photo after signing the MOU. GC Green Cross

Jaeuk Jung, Head of R&D at GC Green Cross (left), and Jongseo Lee, CEO of Abclon, are taking a commemorative photo after signing the MOU. GC Green Cross

View original image

Under this agreement, the two companies will synergistically combine GC Green Cross's mRNA-LNP-based cell-specific expression and delivery technology, as well as its GMP manufacturing capabilities, with Abclone's proprietary CAR-T technology, T cell-specific antibody assets, and extensive clinical experience in CAR-T therapies.


Based on this collaboration, they plan to establish a joint in vivo CAR-T platform and identify innovative new drug candidates targeting various indications, including hematologic cancers. Furthermore, they aim to accelerate entry into preclinical and clinical stages and actively expand global partnerships.


Currently, commercialized CAR-T therapies use an ex vivo approach, where a patient's T cells are extracted from their blood, genetically engineered to recognize cancer cells, expanded, and then re-infused as a personalized treatment. While this method has demonstrated outstanding efficacy as a groundbreaking therapy in certain hematologic cancers, it faces limitations due to the need for patient-specific manufacturing in specialized facilities, resulting in long production times and high costs. As a result, accessibility to treatment is low, and it has mainly been used for limited patients with no alternative options.


The "in vivo CAR-T" therapy being jointly developed by the two companies is a next-generation approach that delivers antibody genetic information directly to T cells inside the body via mRNA, inducing the in vivo generation of CAR-T cells. Like a vaccine, this off-the-shelf format enables mass production and allows for same-day administration without the need for complex cell extraction from patients, positioning it as a game changer in the cell therapy market.


Global pharmaceutical companies are also focusing on in vivo CAR-T as a key modality that can overcome manufacturing complexity, high costs, and limited accessibility. As a result, competition is intensifying to preemptively secure CAR intellectual property rights and effective candidates based on advanced mRNA-LNP platforms in order to gain market leadership.


Jaeuk Jung, Head of R&D Division at GC Green Cross, stated, "This collaboration will be an important inflection point to demonstrate the competitiveness of the mRNA-LNP platform that GC Green Cross has robustly built. By combining the technologies of both companies, we will overcome the limitations of existing CAR-T therapies and take the lead in offering innovative treatment options to patients."



Jongseo Lee, CEO of Abclone, commented, "In vivo CAR-T is a core technology that will change the paradigm of cell therapy. This partnership with GC Green Cross is a critical turning point in translating Abclone's antibody and CAR-T platform capabilities into real therapeutics. Based on our complementary strengths, we will rapidly establish an in vivo CAR-T program with global competitiveness."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing